ClinicalTrials HQ

A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

Active, not recruiting · NCT03122522 · Registry updated 2026-09-08
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination ImmunotherapyNeoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, metastatic melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasmActive, not recruitingPhase 22026-09-08NCT03122522

2 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Bristol-Myers Squibb422
Memorial Sloan Kettering Cancer Center753

13 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Brigham and Women's Hospital (Data and Specimen Analysis Only)BostonUnited States1
Columbia University (Data Analysis Only)New YorkUnited States1
Hartford Healthcare Alliance (Data Collection Only)HartfordUnited States6
Hospital for Special Surgery (Data Analysis)New YorkUnited States1
Jaykumar ThumarHartfordUnited States1
JOHNS HOPKINS HOSPITAL (Data Analysis Only)BaltimoreUnited States1
Memorial Sloan Kettering Basking RidgeBasking RidgeUnited States189
Memorial Sloan Kettering BergenMontvaleUnited States193
Memorial Sloan Kettering Cancer CenterNew YorkUnited States1000
Memorial Sloan Kettering CommackCommackUnited States189
Memorial Sloan Kettering MonmouthMiddletownUnited States206
Memorial Sloan Kettering NassauUniondaleUnited States193
Memorial Sloan Kettering WestchesterHarrisonUnited States204